Prognosis of inv(16)/t(16;16) @entity3052 ( XXXX ): a survey of 110 cases from the French @entity3052 Intergroup.

@entity1 @entity2008 @entity2592 @entity3052
@entity3052 ( @entity3052 ) carrying inv(16)/t(16;16) @entity2008 are associated with a good prognosis. However, studies of this @entity3052 subtype have been hampered by the few number of @entity1 reported, frequently collectively considered with those with @entity3052 carrying the t(8;21) translocation. We performed a retrospective study in 110 @entity1 with @entity3052 (median age, 34 years) prospectively enrolled in 6 trials conducted in France between 1987 and 1998, with the aim to investigate prognostic factors for complete remission (CR) achievement and outcome of CR @entity1 in this @entity3052 subtype. CR rate was 93%. Bad-prognosis factors for CR achievement were higher white blood cell count (WBC) and lower platelet count (optimal cutpoints at 120 and 30 x 109/L, respectively). At 3 years, estimated overall survival, disease-free survival (DFS), and cumulative incidence of relapse were 58%, 48%, and 42%, respectively. In multivariate analysis, (1) advanced age (optimal cutpoint, 35 years) was the only factor for shorter DFS and (2) advanced age and low platelet count were the 2 factors for shorter survival of CR @entity1 . Outcome of CR @entity1 (1) was not influenced by WBC and cytogenetic findings and (2) was similar among @entity1 allocated to receive allogeneic transplantation, high-dose, or intermediate-dose @entity2592 . Interestingly, advanced age was associated with a trend for more frequent additional chromosome abnormalities and predictive of higher cumulative incidence of relapse rather than death in first CR. These results markedly contrast with those reported in @entity1 with t(8;21) @entity3052 in whom WBC, and not age, was the main high-risk factor for relapse, DFS, and survival.
